Odalasvir is a direct-acting antiviral agent within the NS5A inhibitor class used in the treatment of chronic hepatitis C infection. By inhibiting the NS5A protein, which is essential for viral replication… Read more
Odalasvir is a direct-acting antiviral agent within the NS5A inhibitor class used in the treatment of chronic hepatitis C infection. By inhibiting the NS5A protein, which is essential for viral replication and assembly, this compound serves as a critical therapeutic agent. The category includes comprehensive reference standards for Odalasvir active pharmaceutical ingredients, alongside specialized non-pharmacopeial impurities and stable isotope labelled compounds. These high-quality materials are essential for pharmaceutical laboratories during impurity profiling, method validation, and rigorous quality control processes. Utilizing these validated standards ensures accurate identification and quantification of impurities and metabolites, supporting compliance with regulatory standards throughout the drug development lifecycle. Laboratories rely on these specific chemical entities to maintain consistent analytical precision and confidence in their testing protocols for this antiviral therapy.